NewAmsterdam Pharma NAMS
NASDAQ NAMS
$23.20 -0.96 (-3.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)

Updated

NewAmsterdam Pharma (NAMS) reported Non-Current Deffered Revenue of $222,000 for Q2 2024, down 50.0% from the prior quarter.

Analysis

NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024) Analysis & Trends

At the end of FY2023, NewAmsterdam Pharma posted Non-Current Deffered Revenue of $1.02 million, down 78.7% from FY2022.

  • By year, Non-Current Deffered Revenue came in at $4.79 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn -
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn -
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn -
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn -
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -
10 NewAmsterdam Pharma 2.84 Bn 2.84 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 222,000.00
Mar 31, 2024 444,000.00
Dec 31, 2023 1.02 Mn
Dec 31, 2022 4.79 Mn
API Access

NewAmsterdam Pharma Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=NAMS&period=max&api_key=YOUR_API_KEY